CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Moderate"

3 min read | January 30, 2025 11:22 PM PST | By Team Kalkine Media

CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of — Image source: Shutterstock

CareDx Overview and Expert Outlook

CareDx, Inc (NASDAQ:CDNA) is a notable player in the diagnostics sector, focusing primarily on transplant patients.While three Experts suggest holding the stock, four advocates for buying, reflecting a cautiously optimistic outlook. The stock's average 12-month price target from brokerages is $28.33, providing a benchmark for investor expectations.

Expert Ratings and Strategic Financial Moves

The recent activity on CareDx has been dynamic. For instance, BTIG Research recently lowered its target price from $40.00 to $35.00 but maintained a buy rating, indicating confidence in the company's potential resurgence. On a similar note, The Goldman Sachs Group adjusted its target price upwards from $26.00 to $35.00, reinforcing its buy rating.

Insider and Institutional Transactions

CareDx’s recent insider trading and institutional transactions reveal diverse strategies among stakeholders. Notably, Director Peter Maag sold 5,000 shares at an average price of $25.00, resulting in a modest position decrease of 1.49%. Currently, insiders hold 4.90% of the stock.

Institutional investment activity has been pronounced, with hedge funds and other investors adjusting their positions. Quarry LP, for instance, acquired a new position valued at approximately $27,000 during the third quarter. Meanwhile, Harvest Fund Management Co. Ltd, KBC Group NV, and nVerses Capital LLC made calculated investments, the latter increasing its holdings by a substantial 175%. Quest Partners LLC also boosted its stake by 37.8%, indicating growing interest among diverse investment groups.

Financial Performance and Market Standing

CareDx commenced trading at $22.98, experiencing fluctuations between a low of $7.42 and a high of $34.84 over the past year. With a market capitalization of $1.23 billion, the company holds a negative P/E ratio of -8.51, indicated a complex financial landscape. Nevertheless, a beta of 1.86 suggests a more volatile yet potentially rewarding investment.

Recent earnings results were promising, revealing a loss per share of ($0.14), outperforming consensus estimates by $0.11. Revenue increased by 23.4% year-over-year, reaching $82.88 million, and surpassing Expert expectations. Despite a negative net margin of 45.90% and a return on equity of -53.70%, earnings have shown significant improvements compared to the prior year.

Company Profile and Market Strategy

CareDx is distinguished by its robust portfolio of diagnostic solutions catering to the transplant community in the United States and internationally. Its offerings include the AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung solutions, each serving specific transplant requirements through advanced diagnostic technology.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.